8-K
filed April 24, 2026, 7:59 PM ET
ticker CTXR
CIK 0001506251
other material
confidence high
sentiment neutral
materiality 0.50
Citius Pharma raises $5M via registered direct offering and private placement
Citius Pharmaceuticals, Inc.
- Sold 5,076,143 shares/pre-funded warrants at $0.985 each; raised ~$5M gross, $4.5M net.
- Issued unregistered warrants to purchase 5,076,143 shares at $0.86, 5-year term, cashless exercise.
- Net proceeds to fund commercial launch of LYMPHIR and development of product candidates.
- 45-day lock-up on further equity issuance after closing; H.C. Wainwright acted as placement agent.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-26-047599
- form_type
- 8-K
- ticker
- CTXR
- cik
- 0001506251
- company_name
- Citius Pharmaceuticals, Inc.
- filed_at
- 2026-04-24T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.385162+00:00
- generated_at
- 2026-05-15T04:11:47.886445+00:00
- sec_items
- ["1.01", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.5
- calibrated_materiality_score
- 0.5
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-26-047599
- json_url
- https://secwatch.observer/filing/0001213900-26-047599.json
- markdown_url
- https://secwatch.observer/filing/0001213900-26-047599.md
- text_url
- https://secwatch.observer/filing/0001213900-26-047599.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1506251/000121390026047599/0001213900-26-047599-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1506251/000121390026047599/ea0287620-8k_citius.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GIPR
Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit
GENERATION INCOME PROPERTIES, INC.
June 1, 2026, 5:27 PM ET
other_material
Items 1.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.
Comparable filing
In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent
Filing page
SEC filing
LOKV
Live Oak enters Forward Purchase Agreement to back Teamshares merger, up to 4M shares at ~$10.54
Live Oak Acquisition Corp. V
June 1, 2026, 5:00 PM ET
other_material
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.
Comparable filing
On June 1, 2026, Live Oak Acquisition Corp. V, a Cayman Island exempted company (" Live Oak "), and HB Strategies LLC (" Seller " or " FPA Investor ") entered into an agreement (the " Forward Purchase Agreement ") for an OTC Prepaid Share Forward Transaction-Optional Early Termination (the " Forward Purchase Transaction ") in connection with Live Oak’s proposed initial business combination (the " Business Combination ") with Teamshares Inc., a Delaware corporation (" Teamshares " and the surviving public company following consummation of the Business Combination, the " Combined Company "), which is the subject of the previously-disclosed Agreement and Plan of Merger entered into by Live Oak and Teamshares as of November 14, 2025 (as amended as of April 1, 2026, and as may be further amended or supplemented from time to time, the " Merger Agreement ").
Filing page
SEC filing
BRANDYWINE OPERATING PARTNERSHIP, L.P.
Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP
BRANDYWINE OPERATING PARTNERSHIP, L.P.
June 1, 2026, 4:30 PM ET
other_material
Items 1.01, 2.03, 5.02, 5.07, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.
Comparable filing
tnership, L.P., a Delaware limited partnership (the “Operating Partnership” and, together with the Company, the “Borrowers”) extended the maturity date of the Borrowers’ revolving credit facility (the “Revolving Credit Facility”) provided under the Borrowers’ Second Amended and Restated Credit Agreement, dated as of June 30, 2022 (the “Credit Agreement”), by and among the Borrowers, Bank of America, N.A., as administrative agent and lender, and the other agents and lenders party thereto, for a period of six months from June 30, 2026 to December 30, 2026.
Filing page
SEC filing
CITR
CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights
CitroTech Inc.
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.
Comparable filing
On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock
Filing page
SEC filing
LTRX
Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M
LANTRONIX INC
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.
Comparable filing
On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock
Filing page
SEC filing
CPSH
CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share
CPS TECHNOLOGIES CORP/DE/
June 1, 2026, 9:35 AM ET
other_material
Items 1.01, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.
Comparable filing
On May 27, 2026, CPS Technologies Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (the “Investors”) for the sale by the Company of 1,200,000 shares (the “Shares”) of its Common Stock, par value $0.01 per share (“Common Stock”), in a registered direct offering (the “Offering”), at a purchase price of $8.00 per share.
Filing page
SEC filing
SNYR
Synergy CHC enters up to $36M equity purchase agreement with Hudson Global Ventures
Synergy CHC Corp.
May 11, 2026, 7:59 PM ET
other_material
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.
Comparable filing
On May 8, 2026, Synergy CHC Corp. (the “Company”) entered into an equity purchase agreement (the “Purchase Agreement”) with Hudson Global Ventures, LLC (the “Investor”), pursuant to which the Company has the right, but not the obligation, to direct the Investor to purchase up to $36,000,000 of the Company’s common stock
Filing page
SEC filing
BNAI
BEN invests $1M in Accelevate, signs exclusive Mexico reseller and global deal
Brand Engagement Network Inc.
May 11, 2026, 7:59 PM ET
other_material
Items 1.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.
Comparable filing
On May 7, 2026, following the successful completion of due diligence, entered into two definitive Reseller Agreements (the “Commercial Agreements”) with Accelevate.
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.